May an employer-sponsored health plan offer indication-based coverage for GLP-1 medications
The ACHIEVE-3 trial provided the first head-to-head comparison, showing orforglipron superior to oral semaglutide for both glycemic control and weight loss in type 2 diabetes
Oral Non Peptide GLP 1 Receptor Agonist Market Size, Share & Trends Analysis by Type (Small Molecule GLP-1 Agonists, Peptide-Based Oral Formulations, Combination GLP-1 Therapies), by Application (Obesity & Weight Management, Type 2 Diabetes, Cardiovascular Risk Reduction, Non-Alcoholic Steatohepatitis (NASH)), by Distribution Channel (Retail Pharmacy, Telehealth & Direct-to-Patient, Hospital & Clinic), and Segment Forecasts, 2026 to 2035 Non-peptide oral GLP-1 receptor agonists refer to small molecules of drugs, which have the capability of activating the receptors of GLP-1 without the use of peptides as active compounds
The numbers: 28.7% average weight loss over 68 weeks
These side effects are most common in the beginning weeks of treatment and tend to subside as your body adjusts to the medication
For intramuscular or intravenous use
